Physician profile
Hope E Landis
NPI 1477803252
$1,002.32
in general payments reported to CMS, 2019-2025
16 companies · $59.45 in 2025
The $59.45 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $206 · 2023: $192 · 2024: $358 · 2025: $59.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $284.49 | 2021-2024 | Xarelto |
| Ucb, INC. | $150.79 | 2022-2024 | Briviact |
| Pfizer INC. | $131.70 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $82.90 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $78.58 | 2024-2025 | Terlivaz |
| Abbvie INC. | $66.66 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $49.52 | 2024 | |
| Pharmacosmos Therapeutics INC. | $32.47 | 2023 | Monoferric |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.48 | 2024 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $17.03 | 2024 | |
| Paratek Pharmaceuticals, INC. | $15.72 | 2023 | Nuzyra |
| Avanir Pharmaceuticals, INC. | $13.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.57 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.25 | 2024 | Lifevest |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Landis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.